News

The Israeli diagnostics company Improdia has signed a cooperation agreement with Tel Aviv Sourasky Medical Center (Ichilov) to perform a large-scale clinical trial on diabetes

A Novel  Biomarker SNX9  For Chronic Inflammation and associated Immunosuppression and a new regulator of T-Cell expression and  receptor expression and function A new Improdias`

Prof. Dedi Meiri, a lecturer and researcher in the field of medical cannabis at the Technion Institute of Technology, Haifa, and head of its Laboratory